Regional Analysis

Sickle Cell Disease Treatment Market Regional Insights

To learn more about this report, Request sample copy

North America Sickle Cell Disease Treatment Market Trends

North America’s dominance in the sickle cell disease treatment market with a share of 35.3% in 2025 can be attributed to the strong presence of major pharmaceutical companies such as Pfizer Inc. in the region. Favorable government policies have also promoted high healthcare spending and development of advanced treatment options.

Asia Pacific Sickle Cell Disease Treatment Market Trends

The Asia Pacific region exhibits the fastest growth with a share of 27.7% in 2025, led by countries like India, China, and Southeast Asian nations. Rising healthcare expenditure, growing patient awareness, and efforts by governments to expand access to affordable treatment are driving the market growth in the region.

Sickle Cell Disease Treatment Market Outlook for Key Countries

U.S. Sickle Cell Disease Treatment Market Trends

The U.S. sickle cell disease treatment market is set to witness significant growth, fueled by increased awareness, advanced R&D investments, and a high prevalence of sickle cell disease. In October 2023, Editas Medicine, a clinical-stage genome editing company, achieved a significant milestone when the U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, its gene-editing therapy designed for the treatment of sickle cell disease.

U.K. Sickle Cell Disease Treatment Market Trends

The U.K. leads the sickle cell disease treatment market, driven by its pioneering advancements in medical innovation. Notably, In November, 2023, the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) approved Casgevy, the first CRISPR-based (Clustered Regularly Interspaced Short Palindromic Repeats) gene therapy for treating sickle cell disease and β-thalassemia. This therapy works by editing defective bone marrow genes, restoring lifelong hemoglobin production, alleviating severe symptoms, and significantly reducing the need for transfusions.

South Africa Sickle Cell Disease Treatment Market Trends

South Africa drives the sickle cell disease treatment market through its advanced healthcare infrastructure, high disease burden among infants, In November 2024, the Clinton Health Access Initiative (CHAI) received a transformative three-year, US$ 8 million grant from Open Philanthropy to improve access to sickle cell disease (SCD) care in low- and middle-income countries. SCD, a leading cause of death in children under five, disproportionately affects South African infants, with up to 90% of untreated cases resulting in death.

India Sickle Cell Disease Treatment Market Trends

India has a high prevalence of sickle cell disease, particularly in tribal regions. Government initiatives, such as the National Health Mission's focus on screening and awareness programs, aim to improve diagnosis and treatment access, driving market expansion.